IL28B基因在HCV感染中的作用和应用前景
收稿日期: 2013-06-09
修回日期: 2013-07-26
网络出版日期: 2013-10-25
基金资助
国家自然科学基金项目(编号：81260248), 国家科技支撑计划项目(编号：2011BAI15B01-21, 2012BAI39B01)和云南省、昆明理工大学人才培养项目(编号：2010CI006、KKSY201226148)资助
The function and application of the IL28B gene in HCV infection and treatment
Received date: 2013-06-09
Revised date: 2013-07-26
Online published: 2013-10-25
丙型肝炎病毒(Hepatitis C virus, HCV)是造成慢性肝炎、肝硬化乃至肝癌的主要原因之一, 严重威胁人类健康。宿主因素可影响HCV的感染、治疗效果和自然清除率。近期, 欧美多个研究组对自愈和经过治疗的慢性丙型肝炎患者进行了全基因组关联分析(Genome-wide association study, GWAS), 证明IL28B基因(编码IFN-λ3)的单核苷酸多态位点(Single nucleotide polymorphism, SNP)影响HCV患者的治疗效果和自然清除率。IFN-λ3通过与其异源二聚受体IFN-λR1·IL-10R2结合进行信号传导, 上调干扰素刺激基因的表达, 进而发挥抗病毒、抑制肿瘤细胞生长以及免疫调节等生物学功能, 有望成为一种新型抗HCV药物。虽然IL28B基因SNP影响病毒清除的机制尚未清楚, 但其关联分析结果可作为HCV患者临床治疗的辅助指导, 对HCV患者进行IL28B基因遗传易感和功能研究将有助于该病的预防和治疗。
马柯 张阿梅 夏雪山 . IL28B基因在HCV感染中的作用和应用前景[J]. 遗传, 2013 , 35(11) : 1244 -1252 . DOI: 10.3724/SP.J.1005.2013.01244
Hepatitis C virus (HCV) is the etiological factor for Hepatitis C, which is one of the most important pathogenic factors of chronic liver diseases, cirrhosis and even hepatocellular carcinoma. HCV infection brings great threat to human health. Host genetic background could impact HCV infection, viral clearance, and treatment. Recently, some genome-wide association studies (GWAS) of HCV patients were performed. The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-λ3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNα combined with ribavirin (RBV). IFN-λ3 interacts with its acceptor, a heterodimer (IFN-λR1•IL-10R2), and upregulates the IFN-stimulated gene factors (ISGF). IFN-λ3 plays roles in antiviral, antitumor, and immunoloregulation, and thus it might become a potential drug for Hepatitis C treatment. However, the mechanism of the IL28B gene in HCV infection and treatment is unclear, and further studies are needed to reveal the veils and provide theoretical basis for developing a new antiviral drug in clinic.
Key words： hepatitis C; the IL28B gene; response to treatment; viral clearance
[1]Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244(4902): 359–362. <\p>
[2]Kang SM, Choi SH, Park CY, Kim MH, Kim TK, Park JM, Koh MS, Kang HJ, Hwang SB. Monoclonal antibody rec-ognizing N-terminal epitope of hepatitis C virus non-structural 5B inhibits viral RNA replication. J Viral Hepat, 2008, 15(4): 305–313. <\p>
[3]Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology, 2004, 39(1): 5–19.<\p>
[4]Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, Iliopoulos. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular on cogenesis. Cell, 2011, 147(6): 1233–1247.<\p>
[5]Easton DF, Pooley KA, Dunning AM. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447(7148): 1087–1093.<\p>
[6]Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CN, Doney AS, Morris AD, Smith GD, Hattersley AT, McCarthy MI. A common variant in the FTO gene is associated with body mass index and predis-poses to childhood and adult obesity. Science, 2007, 316(5826): 889–894.<\p>
[7]Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jack-son AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu TL, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Sara-mies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 2007, 316(5829): 1341–1345.<\p>
[8]Kanda T, Wu S, Kiyohara T, Nakamoto S, Jiang X, Miya-mura T, Imazeki F, Ishii K, Wakita T, Yokosuka O. Inter-leukin-29 suppresses hepatitis A and C viral internal ribo-somal entry site-mediated translation. Viral Immunol, 2012, 25(5): 379–386.<\p>
[9]Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 2003, 4(1): 69–77.<\p>
[10]Sheppard P, Kindsvogel W, Xu WF, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Pres-nell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cy-tokine receptor IL-28R. Nat Immunol, 2003, 4(1): 63–68.<\p>
[11]Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creat-ing a new interferon gene IFNL4 is associated with im-paired clearance of hepatitis C virus. Nat Genet, 2013, 45(2): 164–171.<\p>
[12]Pestka S, Krause CD, Walter MR. Interferons, inter-feron-like cytokines, and their receptors. Immunol Rev, 2004, 202(1): 8–32.<\p>
[13]Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR,
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
